Association details:
Evidence Level:
Sensitive: C2 – Inclusion Criteria

GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study

Have one of the following targeted sequencing results 1) CD274 amplification 2) positive for mutations causing a hypermutation (PMS1, PMS2, MLH1, MLH3, MSH2, MSH3, MSH6, POLD1, POLD2, or POLE) 3) microsatellite instability (MSI high) 4) somatic exonic mutation rate-high 5) EBV positive
Trial ID: